CAIRE Acquires Spirosure

Respiratory equipment maker picks up developer of technology used to measure a key indicator of allergic inflammation in asthmatic patients.

• By David Kopf
• Jun 04, 2020

Respiratory equipment maker CAIRE Inc. has acquired Spirosure Inc., which has developed technology for measuring Fractional Exhaled Nitric Oxide (FeNO), a key indicator of allergic inflammation in asthmatic patients.

Recent Global Initiative for Asthma (GINA) guidelines recommend FeNO measurement as an assessment tool in the management of the world’s more than 300 million asthma patients.

FeNO can be used to:

• Diagnose asthma
• Detect nonadherence to inhaled corticosteroids (ICS)
• Serve as an early sign of worsening asthmatic inflammation
• Manage difficult-to-control asthma because an elevated FeNO level can be predictive of a good response to ICS.

Spirosure, which will operate the CAIRE Diagnostics Inc. division of CAIRE, recently launched its first product to market, the Fenom Pro, a device that measures FeNO at parts-per-billion levels using a proprietary sensor technology. The product is intended to be used in the clinic setting and is currently available in the United States, the EU and India.

“CAIRE shares our commitment to technological leadership and, with its large international organization, is well-positioned to realize the full potential of our proprietary technology both commercially and with regard to our development pipeline. We look forward to an exciting future as part of CAIRE,” said Solomon Ssenyange, PhD, CEO and chairman of Spirosure.

“FeNO is quickly becoming recognized by the clinical community as an important diagnostic and management tool for clinicians who treat asthma patients,” said Earl Lawson, president and CEO of CAIRE. “The acquisition of Spirosure further diversifies our portfolio and provides access to the $5 billion respiratory diagnostic sector, a market segment where we anticipate rapid growth and adoption.”